SEC Comment Letter 0000000000-25-011844 to FibroBiologics, Inc. (FBLG)

FibroBiologics, Inc.
Date: Dec. 29, 2025 · CIK: 0001958777 · Accession: 0000000000-25-011844

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-292407

Date

December 29, 2025

Author

Pete O’Heeron

Form

UPLOAD

Company

FibroBiologics, Inc.

Letter

December 29, 2025 Pete O’Heeron Chief Executive Officer FibroBiologics, Inc. 455 E. Medical Center Blvd. Suite 300 Houston, TX 77598 Re:FibroBiologics, Inc. Registration Statement on Form S-1 Filed December 23, 2025 File No. 333-292407 Dear Pete O’Heeron: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

December 29, 2025
Pete O’Heeron
Chief Executive Officer
FibroBiologics, Inc.
455 E. Medical Center Blvd.
Suite 300
Houston, TX 77598
Re:FibroBiologics, Inc.
Registration Statement on Form S-1
Filed December 23, 2025
File No. 333-292407
Dear Pete O’Heeron:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io